About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Merck & Cie et al. v. Watson Pharmaceuticals, Inc. et al.
2:12-cv-00223; filed February 13, 2012 in the District Court of Nevada
• Plaintiffs: Merck & Cie; Bayer Pharma AG; Bayer Healthcare Pharmaceuticals Inc.
• Defendants: Watson Pharmaceuticals, Inc.; Watson Laboratories Inc.
Merck & Cie et al. v. Watson Pharmaceuticals Inc. et al.
1:12-cv-00161; filed February 10, 2012 in the District Court of Delaware
• Plaintiffs: Merck & Cie; Bayer Pharma AG; Bayer HealthCare Pharmaceuticals Inc.
• Defendants: Watson Pharmaceuticals Inc.; Watson Laboratories Inc.
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 6,441,168 ("Stable Crystalline Salts of 5-methyltetrahydrofolic Acid," issued August 27, 2002) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Merck's Beyaz® (drospirenone, 17α-ethinyl estradiol, and levomefolate calcium, used for oral contraception). View the Delaware complaint here.
Please see full update below for more information.
Please see full publication below for more information.